You’ll find research from the Witkiewicz-Knudsen Lab in prominent cancer journals, including Frontiers in Oncology, Cancer Discovery, Trends in Cancer, Oncogene, Cell Reports and more.
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
- Journal: Cell Reports, March 2022
- Authors: Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK
- Citation: Cell Rep. 2022 Mar 1;38(9):110448. doi: 10.1016/j.celrep.2022.110448
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center
- Journal: The Oncologist, August 2022
- Authors: Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O'Connor T, Levine E, Witkiewicz AK
- Citation: Oncologist. 2022 Aug 5;27(8):646-654. doi: 10.1093/oncolo/oyac089
- Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H; National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025 Jun 3. doi: 10.1038/s41568-025-00824-9. Epub ahead of print. PMID: 40461793.
- Dommer AP, Kumarasamy V, Wang J, O'Connor TN, Roti M, Mahan S, McLean K, Knudsen ES, Witkiewicz AK. Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer Res. 2025 Apr 3;85(7):1310-1326. doi: 10.1158/0008-5472.CAN-24-2244. PMID: 39945638; PMCID: PMC11977231.
- Kumarasamy V, Wang J, Roti M, Wan Y, Dommer AP, Rosenheck H, Putta S, Trub A, Bisi J, Strum J, Roberts P, Rubin SM, Frangou C, McLean K, Witkiewicz AK, Knudsen ES. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat Commun. 2025 Feb 9;16(1):1476. doi: 10.1038/s41467-025-56674-4. PMID: 39924553; PMCID: PMC11808123.
- Patel R, Fountzilas C, Horowitz M, Schultz E, Clayback KM, Knudsen ES, Witkiewicz AK, Onel K. Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant. Fam Cancer. 2025 May 26;24(2):46. doi: 10.1007/s10689-025-00475-7. PMID: 40418431.
- Tzetzo SL, Schultz E, Wang J, Rosenheck HR, Mahan S, Knudsen ES, Witkiewicz AK. Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer. NPJ Breast Cancer. 2025 Jun 12;11(1):54. doi: 10.1038/s41523-025-00767-2. PMID: 40506447; PMCID: PMC12162882.
- Witkiewicz AK, Wang J, Schultz E, O'Connor TN, O'Connor T, Levine E, Knudsen ES. Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer. Oncogene. 2025 May;44(19):1387-1399. doi: 10.1038/s41388-025-03308-0. Epub 2025 Feb 26. PMID: 40011574.
- O'Connor TN, Schultz E, Wang J, O'Connor T, Levine E, Knudsen ES, Witkiewicz AK. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy. Cancers (Basel). 2024 Apr 30;16(9):1749. doi: 10.3390/cancers16091749. PMID: 38730702; PMCID: PMC11083425.
- Wu J, Wang J, O'Connor TN, Tzetzo SL, Gurova KV, Knudsen ES, Witkiewicz AK. Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models. Mol Cancer Ther. 2024 Aug 16. doi: 10.1158/1535-7163.MCT-24-0369. Epub ahead of print. PMID: 39148328.
- Kumarasamy V, et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 2024 Jan 31. doi: 10.1158/0008-5472.CAN-23-2504.
- Kumarasamy V, et al. Pharmacologically targeting KRAS G12D in PDAC models: tumor cell intrinsic and extrinsic impact. bioRxiv [Preprint]. 2023 Apr 20:2023.03.18.533261. doi: 10.1101/2023.03.18.533261. PMID: 37162905; PMCID: PMC10168422.
- Matsukawa T, et al. Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. FASEB J. 2022 Sep;36(9):e22430. doi: 10.1096/fj.202200061RR. PMID: 35920299; PMCID: PMC9377154.
- Langille E, et al. Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. Cancer Discov. 2022 Dec 2;12(12):2930-2953. doi: 10.1158/2159-8290.CD-21-0865. PMID: 36108220; PMCID: PMC9812400.
- Kumarasamy V, et al. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Oncogene. 2022 Jul;41(27):3524-3538. doi: 10.1038/s41388-022-02362-2. Epub 2022 Jun 9. PMID: 35676324.
- Finnegan RM, et al. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. Front Oncol. 2023 Jan 18;12:966441. doi: 10.3389/fonc.2022.966441. PMID: 36741704; PMCID: PMC9890056.
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
- Journal: Trends in Cancer, September 2022
- Authors: Witkiewicz AK, Kumarasamy V, Sanidas I, Knudsen ES
- Citation: Trends Cancer. 2022 Sep;8(9):711-725. doi: 10.1016/j.trecan.2022.04.006
Contact the Witkiewicz-Knudsen Lab
Department of Molecular and Cellular Biology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263